These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 322921)

  • 81. Aterial blood pressure in dogs: effects of m-tyrosine alone or in combination with inhibitors of aromatic amino acid decarboxylase; relative hypotensive potencies of L-dopa, DL-m-tyrosine, and L-m-tyrosine.
    Minsker DH; Stokes AL
    Experientia; 1974 Sep; 30(9):1051-3. PubMed ID: 4412113
    [No Abstract]   [Full Text] [Related]  

  • 82. Hypotensive action and side-effects of flutonidin in normal subjects. A double-blind controlled trial.
    Sala P; Chierichetti SM; Ferrari P
    Eur J Clin Pharmacol; 1979; 16(6):375-9. PubMed ID: 393519
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Effect of L-dopa alone and in combination with an extracerebral decarboxylase inhibitor on blood pressure and some cardiovascular reflexes.
    Watanabe AM; Chase TN; Cardon PV
    Clin Pharmacol Ther; 1970; 11(5):740-6. PubMed ID: 5455636
    [No Abstract]   [Full Text] [Related]  

  • 84. The central hypotensive effect of clonidine. Studies in tetraplegic subjects.
    Reid JL; Wing LM; Mathias CJ; Frankel HL; Neill E
    Clin Pharmacol Ther; 1977 Apr; 21(4):375-81. PubMed ID: 321174
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Methyldopa and neural control of circulation in essential hypertension.
    Mancia G; Ferrari A; Gregorini L; Bianchini C; Terzoli L; Leonetti G; Zanchetti A
    Am J Cardiol; 1980 Jun; 45(6):1237-43. PubMed ID: 6990740
    [No Abstract]   [Full Text] [Related]  

  • 86. Interactions of levodopa with inhibitors of monoamine oxidase and L-aromatic amino acid decarboxylase.
    Teychenne PF; Calne DB; Lewis PJ; Findley LJ
    Clin Pharmacol Ther; 1975 Sep; 18(3):273-7. PubMed ID: 1164817
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Action of L- -methyldopa-hydrazine on the blood pressure of patients receiving levodopa.
    Calne DB; Petrie A; Rao S; Reid JL; Vakil SD
    Br J Pharmacol; 1972 Jan; 44(1):162-4. PubMed ID: 5015036
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Pharmacodynamic studies with a specific alpha 2-adrenoceptor agonist (BHT-933) in man.
    Rubin PC; Howden CW; McLean K; Reid JL
    J Cardiovasc Pharmacol; 1982; 4(4):527-30. PubMed ID: 6181324
    [TBL] [Abstract][Full Text] [Related]  

  • 89. An intra-arterial profile of methyldopa.
    Gould BA; Hornung RS; Kieso HA; Cashman PM; Raftery EB
    Clin Pharmacol Ther; 1983 Apr; 33(4):438-44. PubMed ID: 6831822
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Orally administered methyldopa. Hemodynamic effects in the presence and absence of congestive heart failure.
    Kranz PD; Haft JI; Venkatachalapathy D; Shahabadi AE
    Arch Intern Med; 1974 Sep; 134(3):478-83. PubMed ID: 4853485
    [No Abstract]   [Full Text] [Related]  

  • 91. Effect of methyldopa on prolactin serum concentration. Comparison between normal and sustained-release formulations.
    Baldini M; Cornelli U; Molinari M; Cantalamessa L
    Eur J Clin Pharmacol; 1988; 34(5):513-5. PubMed ID: 3203713
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Modification of the cardiovascular effects of L-dopa in anesthetized dogs by inhibitors of enzymes involved in catecholamine metabolism.
    Robson RD
    Circ Res; 1971 Jun; 28(6):662-70. PubMed ID: 4325846
    [No Abstract]   [Full Text] [Related]  

  • 93. Proceedings: Further studies on the mechanisms of blood pressure lowering effect of L-DOPA and a peripheral decarboxylase inhibitor in hypertensive rats.
    Nakamura K; Nakamura K
    Jpn Heart J; 1974 Mar; 15(2):187-8. PubMed ID: 4546215
    [No Abstract]   [Full Text] [Related]  

  • 94. Short- and long-term efficacy of a calcium-antagonistic agent (nifedipine) combined with methyldopa in the treatment of severe hypertension.
    Guazzi MD; Fiorentini C; Olivari MT; Bartorelli A; Necchi G; Polese A
    Circulation; 1980 May; 61(5):913-9. PubMed ID: 7363435
    [No Abstract]   [Full Text] [Related]  

  • 95. Relation between the hypotensive and renin-suppressing activities of alpha methyldopa in hypertensive patients.
    Leonetti G; Terzoli L; Morganti A; Manfrin M; Bianchini C; Sala C; Zanchetti A
    Am J Cardiol; 1977 Nov; 40(5):762-7. PubMed ID: 920613
    [No Abstract]   [Full Text] [Related]  

  • 96. Effect of central inhibition of the 1-amino acid decarboxylase on the hypotensive action of 5-HT precursors in cats.
    Flórez J; Armijo JA
    Eur J Pharmacol; 1974 Apr; 26(1):108-10. PubMed ID: 4831977
    [No Abstract]   [Full Text] [Related]  

  • 97. Methyldopa.
    Sjoerdsma A
    Br J Clin Pharmacol; 1982 Jan; 13(1):45-9. PubMed ID: 7066154
    [No Abstract]   [Full Text] [Related]  

  • 98. Some paradoxical aspects of the cardiovascular pharmacology of alpha-methyldopa.
    Ingenito AJ; Procita L
    J Clin Pharmacol; 1977; 17(2-3):95-107. PubMed ID: 833345
    [TBL] [Abstract][Full Text] [Related]  

  • 99. The effect of a peripheral decarboxylase inhibitor (carbidopa) on monoamine and neuroendocrine function in man.
    Garfinkel PE; Warsh JJ; Stancer HC; Godse DD; Brown GM; Vranic M
    Neurology; 1977 May; 27(5):443-7. PubMed ID: 558549
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Studies on the formation of alpha-methylnoradrenaline in hypertensive patients treated with alpha-methyldopa.
    Muscholl E; Rahn KH
    Naunyn Schmiedebergs Arch Exp Pathol Pharmakol; 1968; 259(2):215-6. PubMed ID: 4232699
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.